Press release & events

Explicyte is CIR approved!

10 / 28 / 2019

We are proud to announce that the French Ministry for Higher Education and Research has recognised Explicyte / Immusmol SAS as a "Credit Import Recherche" (CIR) approved research and development service provider.

Explicyte obtient l'agrément CIR !

10 / 24 / 2019

Nous sommes heureux de vous informer que le Ministère de l’Enseignement Supérieur, de la Recherche et de l’Innovation a remis un avis favorable au dossier de demande d’agrément Crédit Impôt Recherche déposé par Explicyte / Immusmol SAS.

Explicyte intensifies its efforts in translational research and will be attending the ASCO Annual Meeting 2019 in Chicag

05 / 21 / 2019

By setting new facilities within the cancer center “Institut Bergonié”, Explicyte - in addition to its preclinical research capabilities - strengthens its development towards clinical translational research, to provide new services based on multiparametric experimental biomarker analysis, for target identification and monitoring of the immune response in the context of clinical trials.

 

Orthotopic glioblastoma mouse model in a new shuttle session - Cost-effective & time-saving efficacy studies

04 / 23 / 2019

Our syngeneic glioma mouse model, based on the intracranial inoculation of Luc2-expressing GL261 cells and bioluminescence imaging for tumor growth monitoring, represents a suitable tool for chemo- and immunotherapy assessment. It closely mimics the human disease in terms of tumor progression and anti-tumor response, and recapitulates glioblastoma characteristic features including among others tumor immune cell infiltration and tumor-induced immunosuppression.